Tachycardia News

News

Ventricular tachycardia may predict death in non-ischaemic cardiomyopathy patients

Audrey Abella, 20230424100000

Ventricular tachycardia predicts all-cause death and non-sudden cardiovascular death (NSCVD) in patients with non-ischaemic cardiomyopathy, a study suggests.

Existing risk scores not enough to predict AF outcomes after pulmonary vein isolation

20211002060000

Currently available risk scores are unreliable for predicting recurrent atrial fibrillation (AF) after initial radiofrequency pulmonary vein isolation, a new study has found.

New ESC guidelines zero in on lipids, diabetes, and more

Elvira Manzano, Roshini Claire Anthony, 20191001070306

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

21 Mar 2023

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020

In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.